Limitations of Prostate Specific Antigen Doubling Time Following Biochemical Recurrence After Radical Prostatectomy: Results From the SEARCH Database

Robert J. Hamilton, William J. Aronson, Martha K. Terris, Christopher J. Kane, Joseph C. Presti, Christopher Amling, Stephen J. Freedland

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: Prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy is a powerful predictor of prostate cancer specific and overall death. To calculate prostate specific antigen doubling time requires multiple prostate specific antigen determinations that are unaltered by secondary therapy and separated by sufficient time. Physicians and patients may be unwilling to wait before starting secondary therapy, especially for high risk recurrences. Hence, those with calculable prostate specific antigen doubling time may represent a select lower risk group relative to all men with biochemical recurrence. Materials and Methods: We compared clinical and pathological features between patients with and without calculable prostate specific antigen doubling time. We assessed time trends in the proportion with calculable prostate specific antigen doubling time in 535 patients with biochemical recurrence after radical prostatectomy at 5 Veterans Affairs medical centers comprising the SEARCH (Shared Equal Access Regional Cancer Hospital) database between 1988 and 2003. Results: Prostate specific antigen doubling time was not calculable in 187 patients (35%) due to secondary therapy in 155 (83%). With time the proportion of patients with calculable prostate specific antigen doubling time decreased significantly (p

Original languageEnglish (US)
Pages (from-to)1785-1790
Number of pages6
JournalJournal of Urology
Volume179
Issue number5
DOIs
StatePublished - May 2008
Externally publishedYes

Fingerprint

Cancer Care Facilities
Prostate-Specific Antigen
Prostatectomy
Databases
Recurrence
Veterans
Prostatic Neoplasms
Therapeutics
Physicians

Keywords

  • local
  • neoplasm recurrence
  • prostate
  • prostate-specific antigen
  • prostatectomy
  • prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Limitations of Prostate Specific Antigen Doubling Time Following Biochemical Recurrence After Radical Prostatectomy : Results From the SEARCH Database. / Hamilton, Robert J.; Aronson, William J.; Terris, Martha K.; Kane, Christopher J.; Presti, Joseph C.; Amling, Christopher; Freedland, Stephen J.

In: Journal of Urology, Vol. 179, No. 5, 05.2008, p. 1785-1790.

Research output: Contribution to journalArticle

Hamilton, Robert J. ; Aronson, William J. ; Terris, Martha K. ; Kane, Christopher J. ; Presti, Joseph C. ; Amling, Christopher ; Freedland, Stephen J. / Limitations of Prostate Specific Antigen Doubling Time Following Biochemical Recurrence After Radical Prostatectomy : Results From the SEARCH Database. In: Journal of Urology. 2008 ; Vol. 179, No. 5. pp. 1785-1790.
@article{a52f41fc7bbb4197a5ef1efbb41d5c5b,
title = "Limitations of Prostate Specific Antigen Doubling Time Following Biochemical Recurrence After Radical Prostatectomy: Results From the SEARCH Database",
abstract = "Purpose: Prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy is a powerful predictor of prostate cancer specific and overall death. To calculate prostate specific antigen doubling time requires multiple prostate specific antigen determinations that are unaltered by secondary therapy and separated by sufficient time. Physicians and patients may be unwilling to wait before starting secondary therapy, especially for high risk recurrences. Hence, those with calculable prostate specific antigen doubling time may represent a select lower risk group relative to all men with biochemical recurrence. Materials and Methods: We compared clinical and pathological features between patients with and without calculable prostate specific antigen doubling time. We assessed time trends in the proportion with calculable prostate specific antigen doubling time in 535 patients with biochemical recurrence after radical prostatectomy at 5 Veterans Affairs medical centers comprising the SEARCH (Shared Equal Access Regional Cancer Hospital) database between 1988 and 2003. Results: Prostate specific antigen doubling time was not calculable in 187 patients (35{\%}) due to secondary therapy in 155 (83{\%}). With time the proportion of patients with calculable prostate specific antigen doubling time decreased significantly (p",
keywords = "local, neoplasm recurrence, prostate, prostate-specific antigen, prostatectomy, prostatic neoplasms",
author = "Hamilton, {Robert J.} and Aronson, {William J.} and Terris, {Martha K.} and Kane, {Christopher J.} and Presti, {Joseph C.} and Christopher Amling and Freedland, {Stephen J.}",
year = "2008",
month = "5",
doi = "10.1016/j.juro.2008.01.040",
language = "English (US)",
volume = "179",
pages = "1785--1790",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Limitations of Prostate Specific Antigen Doubling Time Following Biochemical Recurrence After Radical Prostatectomy

T2 - Results From the SEARCH Database

AU - Hamilton, Robert J.

AU - Aronson, William J.

AU - Terris, Martha K.

AU - Kane, Christopher J.

AU - Presti, Joseph C.

AU - Amling, Christopher

AU - Freedland, Stephen J.

PY - 2008/5

Y1 - 2008/5

N2 - Purpose: Prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy is a powerful predictor of prostate cancer specific and overall death. To calculate prostate specific antigen doubling time requires multiple prostate specific antigen determinations that are unaltered by secondary therapy and separated by sufficient time. Physicians and patients may be unwilling to wait before starting secondary therapy, especially for high risk recurrences. Hence, those with calculable prostate specific antigen doubling time may represent a select lower risk group relative to all men with biochemical recurrence. Materials and Methods: We compared clinical and pathological features between patients with and without calculable prostate specific antigen doubling time. We assessed time trends in the proportion with calculable prostate specific antigen doubling time in 535 patients with biochemical recurrence after radical prostatectomy at 5 Veterans Affairs medical centers comprising the SEARCH (Shared Equal Access Regional Cancer Hospital) database between 1988 and 2003. Results: Prostate specific antigen doubling time was not calculable in 187 patients (35%) due to secondary therapy in 155 (83%). With time the proportion of patients with calculable prostate specific antigen doubling time decreased significantly (p

AB - Purpose: Prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy is a powerful predictor of prostate cancer specific and overall death. To calculate prostate specific antigen doubling time requires multiple prostate specific antigen determinations that are unaltered by secondary therapy and separated by sufficient time. Physicians and patients may be unwilling to wait before starting secondary therapy, especially for high risk recurrences. Hence, those with calculable prostate specific antigen doubling time may represent a select lower risk group relative to all men with biochemical recurrence. Materials and Methods: We compared clinical and pathological features between patients with and without calculable prostate specific antigen doubling time. We assessed time trends in the proportion with calculable prostate specific antigen doubling time in 535 patients with biochemical recurrence after radical prostatectomy at 5 Veterans Affairs medical centers comprising the SEARCH (Shared Equal Access Regional Cancer Hospital) database between 1988 and 2003. Results: Prostate specific antigen doubling time was not calculable in 187 patients (35%) due to secondary therapy in 155 (83%). With time the proportion of patients with calculable prostate specific antigen doubling time decreased significantly (p

KW - local

KW - neoplasm recurrence

KW - prostate

KW - prostate-specific antigen

KW - prostatectomy

KW - prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=41749121190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41749121190&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2008.01.040

DO - 10.1016/j.juro.2008.01.040

M3 - Article

C2 - 18343434

AN - SCOPUS:41749121190

VL - 179

SP - 1785

EP - 1790

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -